You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,144,777


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,144,777
Title:B-lymphocyte targeting agents for use in a method for the treatment of a disease
Abstract: The present invention is related to a B-lymphocyte targeting agent for use in a method for the treatment or diagnosis of cardiac insufficiency. Furthermore, it is related to a composition comprising such B-lymphocyte targeting agent and methods for determining whether a patient suffering from cardiac insufficiency is amenable to the use of the B-lymphocyte targeting agent for its treatment.
Inventor(s): Tschope; Carsten (Berlin, DE), Schultheiss; H. P. (Berlin, DE), Escher; Felicitas (Berlin, DE), Volk; Hans-Dieter (Berlin, DE), Reinke; Petra (Berlin, DE)
Assignee: Charite--Universitatsmedizin Berlin (Berlin, DE)
Application Number:13/264,090
Patent Claims:1. A method for treating cardiac insufficiency in a patient, wherein the cardiac insufficiency is caused by dilated inflammatory cardiomyopathy (DCMi), and wherein said method comprises the steps of: obtaining heart tissue from a patient via an endomyocardial biopsy; determining the presence of B-lymphocytes in the heart tissue obtained via the endomyocardial biopsy using a B-lymphocyte targeting agent; and diagnosing the patient with cardiac insufficiency caused by DCMi based on the presence of B-lymphocytes in the heart tissue; and wherein said method further comprises administering a B-lymphocyte targeting agent to the patient having been diagnosed with cardiac insufficiency caused by DCMi, wherein the B-lymphocyte targeting agent binds to, or targets, human CD20, and wherein the B-lymphocyte targeting agent is selected from antibodies, aptamers, spiegelmers, antigen binding polypeptides and anticalines.

2. The method according to claim 1, wherein the B-lymphocytes are present in intercellular space between heart muscle cells and cells of heart vasculature.

3. The method according to claim 1, wherein the B-lymphocyte targeting agent is capable of killing B-lymphocytes.

4. The method according to claim 3, wherein the B-lymphocytes bear at least one antigen selected from the group consisting of CD19, CD20 and CD21.

5. The method according to claim 1, wherein the B-lymphocyte targeting agent is a naked B-lymphocyte targeting agent.

6. The method according to claim 3, wherein the B-lymphocyte targeting agent comprises a further moiety that is useful in the killing of the B-lymphocyte.

7. The method according to claim 6, wherein the further moiety is selected from the group consisting of radioisotopes, cytotoxic agents and immunomodulators.

8. The method according to claim 1, wherein the B-lymphocyte targeting agent is administered in an amount such as to provide a therapeutic effect.

9. The method according to claim 1, wherein the B-lymphocyte targeting agent is an antibody.

10. The method according to claim 9, wherein the antibody is a polyclonal antibody.

11. The method according to claim 9, wherein the antibody is a monoclonal antibody.

12. The method according to claim 9, wherein the antibody is an antibody fragment that binds to the same antigen and/or epitope as the respective antibody.

13. The method according to claim 12, wherein the antibody fragment is selected from the group consisting of F(ab')2, F(ab)2, Fab', Fab, Fv, scFv and sFv.

14. The method according to claim 9, wherein the antibody is a subhuman primate antibody, a murine monoclonal antibody, a chimeric antibody, a humanized antibody or a human antibody.

15. The method according to claim 9, wherein the antibody mediates complement-mediated cytotoxicity and/or antibody-dependent cell-mediated cytotoxicity.

16. The method according to claim 9, wherein the antibody is an anti-CD20antibody.

17. The method according to claim 16, wherein the antibody is rituximab.

18. The method according to claim 1, wherein the B-lymphocyte targeting agent comprises a further moiety which is useful in the killing of the B-lymphocyte.

19. The method according to claim 18, wherein the further moiety is selected from the group consisting of radioisotopes, cytotoxic agents and immunomodulators.

20. The method according to claim 19, wherein the further moiety is a radioisotope.

21. The method according to claim 20, wherein the radioisotope is selected from the group consisting of .sup.198Au, .sup.32P, .sup.125I, .sup.131I, .sup.90Y, .sup.186Re, .sup.188Re, .sup.67Cu, .sup.211At, .sup.213Bi and .sup.225Ac.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.